Zhejiang Huakang Pharmaceutical Co., Ltd. (SHA:605077)
China · Delayed Price · Currency is CNY 16.19
-0.09 (-0.55%)
At close: Jan 23, 2026
SHA:605077 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
Net Income | 249.95 | 268.48 | 371.45 | 319.28 | 236.71 | 307.17 | Upgrade |
Depreciation & Amortization | 200.42 | 200.42 | 172.84 | 106.48 | 85.22 | 60.08 | Upgrade |
Other Amortization | 13.82 | 13.82 | 8.68 | 6.83 | 6.01 | 5.64 | Upgrade |
Loss (Gain) From Sale of Assets | 0.14 | 0.14 | 0.01 | -0.03 | -0.05 | 0.24 | Upgrade |
Asset Writedown & Restructuring Costs | 0.49 | 0.49 | 4.27 | 2.31 | 5.58 | -0.24 | Upgrade |
Loss (Gain) From Sale of Investments | -22.44 | -22.44 | -11.69 | -33.16 | -51.93 | -24.62 | Upgrade |
Provision & Write-off of Bad Debts | 18.62 | 18.62 | 0.17 | 6.89 | - | - | Upgrade |
Other Operating Activities | 292.99 | 22.36 | 21.77 | -1.35 | 6.45 | 14.98 | Upgrade |
Change in Accounts Receivable | -393.33 | -393.33 | 14.25 | -159.75 | -40.49 | -28.69 | Upgrade |
Change in Inventory | -410.94 | -410.94 | -20.14 | -161.1 | -75 | -8.86 | Upgrade |
Change in Accounts Payable | 451.3 | 451.3 | 51.5 | 161.12 | 86.9 | -6.88 | Upgrade |
Change in Other Net Operating Assets | 24.61 | 24.61 | 3 | - | 8.1 | -2.74 | Upgrade |
Operating Cash Flow | 398.59 | 146.5 | 619.47 | 271.98 | 264.32 | 335.24 | Upgrade |
Operating Cash Flow Growth | 43.18% | -76.35% | 127.77% | 2.90% | -21.15% | 19.17% | Upgrade |
Capital Expenditures | -626.43 | -1,430 | -690.7 | -539.75 | -360.93 | -252.95 | Upgrade |
Sale of Property, Plant & Equipment | 0.6 | 0.42 | 1.2 | 11.77 | 0.56 | 0.43 | Upgrade |
Cash Acquisitions | -7.99 | -53.02 | -528.88 | -21 | -47.17 | - | Upgrade |
Divestitures | - | - | - | - | 17.5 | - | Upgrade |
Investment in Securities | -245.4 | -9.5 | - | 47.27 | -890 | -100 | Upgrade |
Other Investing Activities | 72.33 | -94.3 | -40.18 | 565.63 | 25.09 | 4.03 | Upgrade |
Investing Cash Flow | -806.89 | -1,586 | -1,259 | 63.92 | -1,255 | -348.48 | Upgrade |
Long-Term Debt Issued | - | 682.41 | 2,328 | 696.7 | 156.07 | 153.57 | Upgrade |
Long-Term Debt Repaid | - | -798.78 | -490.23 | -192.88 | -182.89 | -156.05 | Upgrade |
Net Debt Issued (Repaid) | 943.43 | -116.37 | 1,838 | 503.82 | -26.82 | -2.48 | Upgrade |
Issuance of Common Stock | 7.72 | 7.72 | 77.37 | - | 1,394 | - | Upgrade |
Common Dividends Paid | -248.33 | -196.56 | -173.09 | -111.94 | -120.34 | -60.83 | Upgrade |
Other Financing Activities | -391.76 | -5.34 | - | - | -26.9 | -0.47 | Upgrade |
Financing Cash Flow | 311.07 | -310.54 | 1,742 | 391.88 | 1,220 | -63.78 | Upgrade |
Foreign Exchange Rate Adjustments | 8.59 | 10.67 | 0.86 | 5.02 | -1.94 | -2.27 | Upgrade |
Net Cash Flow | -88.64 | -1,739 | 1,104 | 732.8 | 227.74 | -79.29 | Upgrade |
Free Cash Flow | -227.84 | -1,283 | -71.23 | -267.77 | -96.61 | 82.29 | Upgrade |
Free Cash Flow Growth | - | - | - | - | - | -44.81% | Upgrade |
Free Cash Flow Margin | -6.22% | -45.69% | -2.56% | -12.17% | -6.06% | 6.24% | Upgrade |
Free Cash Flow Per Share | -0.70 | -3.39 | -0.24 | -0.90 | -0.34 | 0.37 | Upgrade |
Cash Interest Paid | 2.6 | 2.6 | - | - | - | - | Upgrade |
Cash Income Tax Paid | - | -132.84 | -45.42 | -95.23 | 3.57 | -7.2 | Upgrade |
Levered Free Cash Flow | 15.28 | -1,084 | -251.85 | -336.7 | -233.82 | 57.37 | Upgrade |
Unlevered Free Cash Flow | 65.56 | -1,063 | -228.63 | -327.8 | -231.38 | 62.64 | Upgrade |
Change in Working Capital | -353.32 | -353.32 | 47.46 | -135.89 | -23.67 | -28.01 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.